1 / 11

A randomized controlled trial of citalopram on migraine frequency

gaurav
Télécharger la présentation

A randomized controlled trial of citalopram on migraine frequency

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. A randomized controlled trial of citalopram on migraine frequency Satnam S. Nijjar, M.D. Department of Neurology, Johns Hopkins School of Medicine

    2. Burden of Migraine Migraine is highly prevalent: 7.8 % in males and 24.9% in females Migraine has significant impact on the sufferer and on society Estimated cost of $13 billion/year in U.S. Absenteeism Reduced effectiveness

    3. Need for improved prophylaxis No clear first line therapy. Decreased serotonin levels implicated, however little evidence to support selective serotonin reuptake inhibitors. Citalopram is a well established SSRI with a well known safety profile. Reordered.Reordered.

    4. Hypothesis Citalopram will significantly reduce the frequency of episodic migraine compared to placebo in patients who are candidates for migraine prophylaxis.

    5. Study Design

    6. Study Population Inclusion criteria Episodic migraine as defined by International Headache Society Candidates for prophylaxis, not on previous treatment Exclusion criteria chronic migraine analgesic overuse antidepressant therapy Recruitment Approximately 100 adult patients Headache Clinic Johns Hopkins Bayview Medical Center Define HIS, JHBMCDefine HIS, JHBMC

    7. Variables Primary outcome: migraine frequency as assessed by diary Secondary outcomes: Disease specific: Migraine Disability Assessment Scale (MIDAS) and Headache Impact Test (HIT) survey scores Quality of Life: SF-36 survey scores Safety variables Symptom questionnaire Define MIDAS, HITDefine MIDAS, HIT

    8. Statistical Analysis Intention to treat analysis Analytic steps Calculate rates (episodes/month) Compare rates Ratio of rates Difference of rates

    9. Significance Demonstrating the effectiveness of citalopram in migraine prophylaxis may alter current practice Providing clinicians with a new avenue of migraine treatment with a low side effect profile.

    10. Acknowledgements Group Instructors: Dr. Larry Appel Dr. Liz Selvin Dr. Mark Woodward Group Members: Dr. Liudmila Cebotaru, Dr. Ralph Daher, Dr. Andrea Dugas, Dr. Christopher Ennen, Dr. Shannon Haley, and Dr. Milap Nowrangi

    11. Thank you

More Related